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ABSTRACT We focused on transcription factors and
epigenetic marks that regulate the B3GALT5 gene
through its retroviral long terminal repeat (LTR) pro-
moter. We compared the expression levels of the
B3GALT5 LTR transcript, quantitated by competitive
RT-PCR, with those of the candidate transcription
factors HNF1/ and Cdx1/2, determined by Western
blot analysis, in colon cancer biopsies, various cell lines,
and cell models serving as controls. We found that
HNF1/ were easily detected, irrespective of the
amount of LTR transcript expressed by the source,
whereas Cdx1/2 were undetectable, and no sample
lacking HNF1/ expressed the LTR transcript. On
transfection in proper host cells, both HNF1 and
HNF1 provided detectable LTR transcript, whereas
shRNA-mediated silencing of HNF1 impaired tran-
scription. Treating cells with 5=-aza-2=-deoxycytidine
(5AZA) strongly reduced expression, without affecting
HNF1/, despite the lack of CpG islands in the LTR
and proximal sequences. By electrophoresis mobility
shift and luciferase reporter assays, the LTR promoter
binding and activity did not correlate with the amounts
of LTR transcript expressed in the cells and depended
on the levels of the transcription factors. We conclude
that HNF1/ are necessary but insufficient to activate
and regulate B3GALT5 LTR transcription, which de-
pends on unknown regulatory elements that are active
when methylated and located outside of and far from
the LTR promoter.—Zulueta, A., Caretti, A., Signorelli,
P., Dall’Olio, F., Trinchera, M. Transcriptional control
of the B3GALT5 gene by a retroviral promoter and
methylation of distant regulatory elements. FASEB J.
28, 946–955 (2014). www.fasebj.org
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The B3GALT5 gene codes for 1,3 galactosyltrans-
ferase 5, an enzyme responsible for the synthesis of type
1 chain carbohydrates in mammals. In humans, in
particular, it participates in the biosynthesis of the
histo-blood group antigens Lewis a (Gal1–3[Fuc1–
4]GlcNAc), Lewis b (Fuc1-2Gal1–3[Fuc1–
4]GlcNAc), and sialyl-Lewis a (NeuAc2-3Gal1–
3[Fuc1–4]GlcNAc) (1). The latter is a specific selectin
ligand (2, 3) constituting the epitope of the CA19.9
antigen, which circulates in the serum of some patients
with cancer (4, 5). B3GALT5 cDNA was first cloned
from the human colon adenocarcinoma cell line CO-
LO-205. The mRNA that corresponds to the coding
sequence is found in the epithelia of various gastroin-
testinal tissues and some related cell lines (1) and is
strongly down-regulated in colon cancer (6). A single
transcription start site has been recognized, and a
5=-flanking region has been found to act as a promoter.
The hepatocyte nuclear factor 1 (HNF1) and caudal-
related homeobox (Cdx) transcription factors have
been thought to control B3GALT5 expression accord-
ing to a model reported for the typical intestinal
enzyme sucrase-isomaltase (7). Of note, it was found
soon after that the entire exon 1 of this B3GALT5
transcript, as well as the putative HNF1/Cdx-binding
motif in the 5= flanking promoter region, belonged to
a retroviral long terminal repeat (LTR) sequence (8),
also present in Old World monkeys, but not in New
World monkeys or mice. This finding dates the inser-
tion of the transposon to 25–30  106 yr ago, and
suggests the existence of another ancestral promoter
(9). We have characterized multiple B3GALT5 tran-
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scription initiation sites and cognate 5=-untranslated
regions (UTRs), as well as distinct 5= flanking regions
that are active as promoters (10). Among them, the
type A promoter, which is sensitive to the CCAAT-
binding factor (NF-Y) and is also active in mice, has
been proposed as the native promoter. In humans, the
type A promoter is located 42 kbp upstream of the
LTR sequence in the context of CpG islands and
appears to be active in many epithelia, but it is weakly
active and down-regulated in cancer through epige-
netic mechanisms (11). The type B promoter, located
27 kbp upstream of the LTR in humans, appears as a
defective, weak promoter that has the same HNF1/Cdx
binding sequence as the LTR promoter, but the oppo-
site orientation, and is thus thought to be related to the
successful insertion of the transposon (10). The type C
promoter has been found to be a rather strong one,
active in the small intestine only. It is located 17 kbp
upstream of the LTR sequence, and its binding sites for
transcription factors remain unknown. All B3GALT5
transcripts driven by such promoters share a common
3= sequence, including exons 3 (untranslated) and 4
(spanning the entire coding sequence), and differ in
their 5=-UTRs only. Reevaluation of the tissue distribu-
tion of the various B3GALT5 mRNAs (10) indicated
that the LTR transcript is very highly expressed only in
normal colon mucosa, whereas, in the other organs of
the gastrointestinal tract, including the small intestine,
it is present in lower amounts. Such an expression
pattern is thus the opposite of that reported for sucrase-
isomaltase, which is much more active in the small
intestine than in the colon (12). Moreover, it was also
reported that COLO-205 cells, expressing extremely
high levels of B3GALT5 mRNA, including the LTR
transcript (refs. 1, 13 and present work), are devoid of
any Cdx expression (14). These findings appeared to
be incompatible with the proposed model of B3GALT5
transcription and prompted us to reevaluate the model
in detail. In particular, we wanted to elucidate the
role of candidate transcription factors and the pres-
ence of potential epigenetic marks and explain tis-
sue-specific expression and regulation, mainly in the
process of colon tumorigenesis. Moreover, we wanted
a better understanding of the evolutionary stabiliza-
tion of the transposon that occurred in humans and
some primates. To achieve these aims, we compared
the expression levels of the B3GALT5 LTR transcript,
quantitated by competitive reverse transcription-
polymerase chain reaction (RT-PCR), with those of
the candidate transcription factors HNF1/ and
Cdx1/2, determined by Western blot analysis, in
colon cancer biopsies, various cell lines, and cell
models serving as controls. The models included cells
transfected with plasmids coding HNF1/ cDNAs or
shRNAs or treated with the demethylating agent 5=-aza-
2=-deoxycytidine (5AZA). We also evaluated the behav-
ior of the LTR promoter in vitro, through electrophoresis
mobility shift (EMSA) and luciferase reporter assays.
MATERIALS AND METHODS
Cell lines, tissues, and cell treatments
The human breast cancer cell lines MCF-7 and MDA-MB-231,
the human gastric cell lines MKN-45 and KATOIII, the
human bile duct carcinoma cell line HuCC-T1, and the
human colon cancer cell lines HT-29, HCT-15, COLO-205,
and SW-1116 were cultured as reported previously (10, 11, 13,
15). The human breast cancer cell line MDA-MB-361 (a gift of
Dr. Cristina Razzari, University of Milan, Milan, Italy), the
human embryonic kidney (HEK) cell line HEK-293T/17
[American Type Culture Collection (ATCC) CRL-11268, a
gift of Dr. Anna Menini, Scuola Internazionale Superiore di
Studi Avanzati (SISSA), Trieste, Italy], and the human hepa-
toma cell lines Huh-7 and Hep-3B (a gift of the GIM
Microscopy Group; University of Milan), were cultured in
DMEM containing 10% fetal bovine serum, 100 U/ml peni-
cillin, 1 mg/ml streptomycin, and 2 mM l-glutamine. Human
colon biopsies were performed as reported previously (6, 15).
Treatments of cells with drugs affecting DNA methylation and
histone deacetylation were performed as reported previously
(11). The medium was replaced every 24 h with medium
containing freshly diluted drugs. At the end of the treatment,
the cells were harvested by trypsinization and processed for
extraction of total RNA or nuclear protein.
Plasmid DNAs and cell transfections
The coding sequences of HNF1, HNF1, Cdx1, and Cdx2
were obtained by PCR, with the reported primer pairs (7),
harboring HindIII and XbaI restriction sites, starting with
RNA extracted from COLO-205 cells (HNF1), MKN-45 cells
(HNF1), and commercially available (Stratagene 540009;
Agilent Technologies Italia, Milan, Italy) human normal
mucosa RNA (Cdx1 and Cdx2), using the reported proce-
dure (15). Amplified fragments were restriction digested,
cloned into the corresponding sites of the pcDNA3 vector,
and sequenced. Because we obtained the variants P130R (16)
and S291P (17) of Cdx1 and Cdx2, respectively, from our
source, we mutated the plasmids with the QuikChange mu-
tagenesis kit (Agilent Technologies) to obtain the wild-type
sequences, according to the manufacturer’s protocol.
For permanent transfection, 3  106 MDA-MB-231 cells
were seeded in 100-mm plates 24 h in advance, and 20 g of
ScaI-linearized pcDNA3-HNF1, pcDNA3-HNF1, or pcDNA3
alone was mixed with 1 g of XhoI-linearized pLKO-puro
empty vector (Sigma-Aldrich Italia, Milan, Italy) bearing the
puromycin-resistance gene. Transfection solutions were pre-
pared by diluting the linearized DNA with 2 ml of serum-free
medium and then adding 2 ml of serum-free medium con-
taining 60 l Lipofectamine 2000 (Life Technologies Italia,
Monza, Italy). Liposomes were allowed to form for 20 min at
room temperature. The cells were washed twice with serum-
free medium, fed with transfection solution, and incubated
under regular growth conditions for 3–4 h. At the end, 8 ml
of standard complete medium was added, and the incubation
was continued. At 2 d after transfection, the cells were
trypsinized and divided into multiple plates. Selection started
after an additional 24 h in the presence of 1 g/ml puromy-
cin. Resistant colonies were collected, grown, and harvested
to extract nuclear protein and total RNA from the same cell
suspensions.
For transient transfection, 4  106 HEK-293T cells were
seeded in 60-mm plates 24 h in advance, and 5 g of
pcDNA3-Cdx1 or pcDNA3-Cdx2 was transfected in 1.5 ml of
transfection solutions prepared as above for permanent trans-
fection. The next day, the cells were trypsinized and placed in
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100-mm plates in the presence of 2 mg/ml G418. After an
additional 5 d (changing medium twice), resistant cells were
harvested and used for nuclear protein extraction.
For gene silencing, we used Human Mission shRNA Plas-
mid DNA (Sigma-Aldrich Italia), based on the pLKO vector,
clone TRCN0000017509NM_000458.1-800s1c1TRC 1 (target-
ing HNF1), clone TRCN0000017194NM_000545.3-1039s1c1TRC
1 (targeting HNF1), or the pLKO vector alone. They were
linearized with BstEII (to destroy the puromycin-resistance
gene) and mixed with 1:20 of the same plasmid linearized
with ScaI. Transfection of the MKN-45 and MDA-MB-361 cells
and puromycin selection were carried out as for the MDA-
MB-231 cells. Because we found in preliminary experiments
that gene silencing was lost after prolonged cell replications
(over 4 wk), we allowed individual or pooled colonies ob-
tained on selection to grow for only 3 wk, washed the
obtained cell pellets (0.5-1.0106 cells) with sterile PBS,
and divided them into 3 fractions: the first (0.1–0.2106
cells) lysed for RNA extraction, the second (0.4–0.6106
cells) mixed with protease inhibitor cocktail HALT (Thermo
Scientific, Waltham, MA, USA) for direct Western blot anal-
ysis, and the third plated again for further growth. Sequences
were analyzed through the EMBOSS Cpgplot software [Euro-
pean Molecular Biology Laboratory (EMBL), Heidelberg,
Germany].
Western blot analysis
Freshly collected cell pellets were processed to obtain nuclear
extracts, with a commercially available kit (NE-PER; Thermo
Scientific; ref. 11). Frozen biopsies from the colon were
Dounce homogenized and subjected to nuclear extraction as
for the cell pellets. Aliquots of nuclear extracts (5–10 g of
protein) were separated by 10% SDS-PAGE; transferred to a
nitrocellulose membrane (Trans-Blot SD Semi-Dry Transfer
Cell; Bio-Rad Laboratories S.r.l., Milan, Italy); and blotted
with rabbit polyclonal anti-HNF1/ (sc-8986, 1:200; Santa
Cruz Biotechnology Italia, Milan, Italy), rabbit polyclonal
anti-H3 (D2B12 4620, 1:500; Cell Signaling Technology,
Danvers, MA, USA), rabbit polyclonal anti-Cdx1 (PAB4713,
1:200; Abnova, Taipei, Taiwan), or mouse monoclonal anti-
Cdx2 (M01, 1:200; Abnova) antibodies, according to our
published protocol (18).
Competitive RT-PCR
Quantification of transcripts was performed by competitive
RT-PCR, which has been found to be effective for distinguish-
ing different 5=-UTRs without underestimating splice variants
(10). Total RNA, prepared and DNase treated with a com-
mercially available kit (SV total RNA isolation system or
ReliaPrep cell RNA miniprep; both from Promega Italia,
Milan, Italy), was quantitated by fluorometry with Qubit (Life
Technologies Italia) and reverse transcribed (11). cDNAs
were amplified in a volume of 25 l in the presence of the
indicated amounts of competitors (11), for 35 cycles
(B3GALT5 LTR, HNF1, and HNF1) or 5 pg competitor for
25 cycles (-actin). The amplification program included a
single treatment at 94°C for 3 min followed by cycles consist-
ing of 1 min at 94°C (melting), 3.5 min at 72°C (annealing
plus extension), and a final extension step at 72°C for 8 min
(B3GALT5 and -actin) or 1 min at 94°C (melting), 1 min at
66°C (annealing), 2.5 min at 72°C (extension), and a final
extension step at 72°C for 8 min (HNF1 and -). B3GALT5
LTR and -actin competitors and primers were identical with
those already reported (6, 10). The HNF1 competitor was
prepared by subcloning the coding sequence in the pCDM8
vector, digesting with the restriction enzymes BspHI and MscI,
and religating. The HNF1 primers were 5=-CAGAGC-
CATGGGCCTGGGCAGTC-3= (sense) and 5=-CTGCTGGGC-
CATGTGGCTGCCTG-3= (antisense). The HNF1 competitor
was prepared by digesting pcDNA3-HNF1 with the restriction
enzymes XhoI and Bsp1407I, blunting with Klenow, and
religating. The HNF1 primers were 5=-GCCATGGTTTCTA-
AACTGAGCCAG-3= (sense) and 5=-GTCCATAGCGCACACCGT-
GGAC-3= (antisense).
Parallel PCR amplifications were performed on known
amounts of standard cDNAs premixed with the competitors.
Standard cDNAs were the original cloned sequences quanti-
tated and diluted as for the competitors. Aliquots of PCR
reactions were analyzed on 1% agarose gels stained with
ethidium bromide. Quantification was performed by densito-
metric scanning of the gel, and the amounts of amplified
target cDNAs were calculated from their respective standard
curves and normalized by that for -actin. The target:com-
petitor ratios had been shown to make the PCR results
quantitative (19).
Luciferase assay
The DNA fragment containing the sequence from 148 to
128 from the LTR transcription initiation site, cloned in the
pGL3 vector as reported previously (10), was used as the LTR
promoter (pGL3-LTR).
For transfection, 50,000–80,000 host cells were plated 20 h
in advance in 96-well plates with 0.1 ml culture medium.
Transfection solutions were prepared by mixing 200 ng of test
DNA (pGL3-LTR alone or 100 ng pGL3-LTR plus 100 ng
pcDNA3-based plasmids) with 10 ng of the Renilla luciferase
expression vector pRL-CMV (Promega Italia) in 25 l serum-
free medium. Serum-free medium (25 l) containing 0.6 l
Lipofectamine 2000 was then added to the DNA dilution, and
the complete solution was used as above for all other trans-
fections. After the addition of 0.1 ml standard medium, the
incubation was continued for 20 h. The cells were then
washed, lysed, and assayed for luciferase activity (10).
EMSA
EMSAs were performed with the Lightshift chemilumines-
cence kit (Thermo Scientific) according to the manufacturer’s
recommendations, but the binding reaction volume was
scaled down to 10 l. DNA probes biotinylated at the 3= end
were synthesized by Eurofins-MWG Operon (Ebersberg, Ger-
many) and diluted to 1 nM in the assay. Nuclear extracts were
prepared as for Western blot analysis, and 1 l of extract (3–4
g of protein) was added to each binding reaction. Anti-
HNF-1 antibody was incubated for 30 min on ice in the
binding reaction before the probes were added. Cdx compet-
itor DNA was the 24-bp SIF1 sequence 5=-GGGTGCAATA-
AAACTTTATGAGTA-3= deduced from Suh et al. (20). DNA/
protein complexes were separated by 5% native PAGE,
transferred to a nylon membrane, cross-linked under UV
light, and visualized as reported (10).
RESULTS
Detection of HNF1/ and Cdx1/2 in colon cancer
biopsies and cell lines expressing different amounts
of B3GALT5 LTR transcript
In preliminary experiments, we determined the expres-
sion of the B3GALT5 LTR transcript in matched pairs
of biopsies representing colon cancers and surround-
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ing normal mucosae. As expected, owing to the strong
prevalence of the transcript in these tissues, the results
were similar to those that had been obtained measuring
the B3GALT5 coding sequence (6, 7), which is com-
mon to all transcripts. Expression levels, in fact, ranged
from 11 to 1 fg/pg of -actin (average, 3.9) and from
0.5 fg/pg of -actin to undetectable levels (average,
0.13), in normal colon mucosae and colon cancers,
respectively (Supplemental Fig. S1A). In relation to
levels in the matched pairs, the amount of LTR tran-
script decreased in cancer from 4- to 200-fold. To
assess the relationship between the LTR transcript and
the candidate transcription factors HNF1/ and
Cdx1/2, we determined their levels in nuclear protein
extracted from representative biopsies. We had enough
material available for extracting nuclear protein from 8
cancer biopsies, but from only 2 normal mucosa spec-
imens, and we therefore first compared the cancer
samples with various cell lines presenting a wide range
of expression of the LTR transcript. We were surprised
to find that, in all cancer samples tested, HNF1 and
HNF1 were easily detected, whereas Cdx1 and Cdx2
were almost undetectable, irrespective of the amount of
LTR transcript expressed (Fig. 1). We also found that
the COLO-205 and SW-1116 cells, which expressed the
highest amount of LTR transcript (15 and 6 fg/pg of
-actin, respectively), expressed only HNF1, at levels
similar to those in samples expressing low or no LTR
transcript, such as the hepatoma cell lines Huh-7 and
Hep-3B. The MKN-45 and HT-29 cells expressed both
HNF1 and HNF1, but the transcript levels were
lower than in the COLO-205 or SW-1116 cells. In
contrast, the MDA-MB-361 cells expressed only HNF1
and slightly more LTR transcript than did the MKN-45
or HT-29 cells. Of interest, the cells lacking HNF1/
also lacked LTR transcript, but not vice versa. Cdx1 and
Cdx2 remained undetectable under reference condi-
tions in all tested samples. A weak Cdx2 spot became
detectable after a longer exposure in the HCT-15 cells
and in two cancer biopsies expressing no LTR tran-
Figure 1. Detection of transcription factors HNF1/ and Cdx1/2 in human colon cancers and cell lines expressing various
amounts of B3GALT5 LTR transcript. A) RNA extracted from cancers and cell lines was reverse transcribed, and normalized
amounts of the resultant first-strand cDNAs were mixed with the indicated amounts of competitor (truncated) cDNAs and
subjected to PCR (25 and 35 cycles for -actin and B3GALT5 LTR, respectively), using primers specific to -actin and B3GALT5
LTR transcript, respectively. Note the different amounts of B3GALT5 LTR competitor cDNA used in the case of colon cancers,
cell lines (present figure), and matched pairs of colon biopsies (Supplemental Fig. S1A). Twenty percent of each amplification
reaction was electrophoresed in a 1% agarose gel and visualized by ethidium bromide staining. The target doublet corresponded
to the alternative splicing that had been reported (10). Representative gels are shown. Samples were not all run on the same
gel, as indicated by the vertical white spaces between the gels. B) Densitometric scanning of gel images was performed to
quantitate the amounts of B3GALT5 LTR transcript, which were calculated from a standard curve and normalized to the
amounts calculated for -actin. Results are means  sd of 3 determinations. Note the different scales used for colon cancer and
the cell lines. C) Nuclear extracts (5–10 g of protein) were separated by 10% SDS-PAGE and transferred to a nitrocellulose
membrane that was blotted with anti-HNF1 antibody (recognizing both HNF1 and HNF1), or anti-Cdx1, anti-Cdx2, or
anti-histone H3 antibodies, followed by an HRP-labeled secondary antibody and chemiluminescence detection. Longer
exposures were necessary to detect a visible spot for Cdx1 and Cdx2. For comparative quantitation, see Supplemental Fig. S1B.
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script at all. To assess the sensitivity of the anti-Cdx
antibodies, we analyzed the nuclear protein extracted
from the HEK-293T cells transfected with Cdx1 or Cdx2
cDNAs and found very strong signals under the condi-
tions used for detection (Supplemental Fig. S1B). Fi-
nally, in the two available normal colon mucosa biop-
sies (Supplemental Fig. S1C), we detected HNF1/
only. Their levels were not related to those of B3GALT5
LTR transcript, as found in the cancer cell lines.
Detection of B3GALT5 LTR transcript in cell models
expressing various amounts of HNF1 or HNF1
To better assess the role of HNF1/, we planned to
overexpress the factors in a suitable cell model. In
preliminary experiments, we used Western blot analysis
to determine the expression levels of HNF1/ tran-
scripts in cell lines that do not express the protein, such
as HCT-15 and Hucc-T1 (Fig. 1). Both lines unexpect-
edly expressed HNF1 transcript at high levels. We
therefore extended the analysis to many other cell lines
and found that HNF1 RNA was commonly expressed,
even in cells where the protein was undetectable by
Western blot analysis (Supplemental Fig. S2), suggest-
ing a crucial post-transcriptional regulation of the
gene. This phenomenon was not evident in the case of
HNF1 (Supplemental Fig. S2). The breast cancer cell
line MDA-MB-231, lacking both HNF1 and HNF1
transcripts, was thus chosen for the transfection exper-
iments.
The clones, analyzed by Western blot analysis (Fig. 2A,
bottom panels), were found to express various, but
rather high, levels of HNF1, compared with that in the
Huh-7 cells, and various but low levels of HNF1, compared
with that in the MDA-MB-361 cells. B3GALT5 LTR
transcript became detectable, although at low levels, in
all the clones expressing either HNF1 or HNF1 (Fig.
2A, top panel). The amount of LTR transcript, in fact,
ranged from 0.05 to 0.5 fg/pg of -actin. However, even
weak expression of HNF1 induced transcription of
LTR mRNA. In particular, the clones -1 and -4
expressed similar levels of LTR transcript, whereas the
amount of HNF1 in the former was much lower than
that of HNF1 in the latter (Fig. 2A). Notwithstanding
the low levels of HNF1 protein in the clones, the
corresponding amount of transcript was very high, the
highest detected among the tested cells (Supplemental
Fig. S2), confirming that regulation of the HNF1 gene
is largely post-transcriptional. To focus on the role of
HNF1, we silenced HNF1 in the MKN-45 cells, which
express both factors, and HNF1 in the MDA-MB-361
cells, which express HNF1 only. Using plasmids en-
coding shRNAs targeting either factor, we obtained a
transient but strong reduction of expression of HNF1
Figure 2. Effect of HNF1/ expression or silencing on the levels of
B3GALT5 LTR transcript. A) MDA-MB-231 cells, not expressing HNF1 or
HNF1, were transfected with either factor, and the obtained clones were
screened by Western blot analysis with anti-HNF1 antibody. RNA and
nuclear proteins were extracted from positive clones and used for B3GALT5
LTR transcript quantification (competitive RT-PCR) and HNF1/ (West-
ern blot analysis), as reported in Fig. 1. A mock-transfected clone, obtained
using the resistance plasmid mixed with pcDNA3 vector alone, was used as
the control. Huh-7 cells, expressing high levels of HNF1 but not LTR
transcript, and MDA-MB-361 cells, expressing HNF1 only and a moderate amount of LTR transcript, were also used as
references. B) MKN-45 cells, expressing both HNF1 and HNF1, as well as B3GALT5 LTR transcript, were transfected with
the pLKO plasmid bearing an shRNA sequence specifically targeting HNF1. Individual clones resistant to puromycin
selection were allowed to grow for 3 wk, and the cells obtained were used for Western blot analysis, RNA extraction, or
replating for further growth up to 5 wk. A control clone was prepared in parallel transfecting cells with the empty pLKO
vector. Western blot analysis (top panel) and competitive RT-PCR analyses (bottom panels) were then performed as
reported in Fig. 1. Detection of HNF1 was used as internal reference to evaluate HNF1 silencing and re-expression. C)
MDA-MB-361 cells, expressing HNF1 only, as well as B3GALT5 LTR transcript, were transfected with pLKO plasmid
bearing an shRNA sequence that specifically targets HNF1. Individual or pooled clones resistant to puromycin selection
were allowed to grow for 3 wk, and the obtained cells were used for Western blot analysis, RNA extraction, or replating for
further growth up to 5 wk. A control clone was prepared in parallel, transfecting cells with the empty pLKO vector. Western
blot analysis (top panel) and competitive RT-PCR analyses (bottom panels) were then performed as reported in Fig. 1.
Detection of histone H3 was used as internal reference to evaluate HNF1 silencing and reexpression.
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in the MKN-45 cells (Fig. 2B, top panel) and of HNF1
in the MDA-MB-361 cells (Fig. 2C, top panel). The
former had no effect on LTR transcript levels (Fig. 2B,
bottom panel), but the latter was accompanied by a
dramatic reduction of the transcript (Fig. 2C, bottom
panel). After longer periods following transfection,
recovery of HNF1 expression in the MKN-45 cells did
not affect the LTR transcript levels, whereas recovery of
HNF1 expression in the MDA-MB-361 cells restored
the amount of the transcript. These data indicate that
HNF1 and HNF1 play an interchangeable, but not a
cumulative, role, and suggest that, although necessary
for B3GALT5 transcription, they are not sufficient to
explain transcript modulation.
To remove potential epigenetic constraints, we per-
formed trichostatin A (TSA) and 5AZA treatments,
starting with the MKN-45 cells, given that they were
found to be sensitive to such treatments in the case of
the native B3GALT5 transcript (11). We found that
TSA treatment (Fig. 3A) had no effect on the LTR
transcript, whereas, surprisingly, 5AZA strongly im-
paired expression (Fig. 3B). We repeated the treatment
on the COLO-205 cells, because they express LTR
transcript at the highest levels found, and obtained
similar results (Fig. 3B). In fact, even in these cells,
5AZA treatment impaired LTR expression in a dose-
and time-dependent manner. In both treated cell lines,
B3GALT5 LTR transcript dropped down to the levels
measured in some colon cancer biopsies or HNF1/-
transfected MDA-MB-231 clones, whereas the levels of
HNF1 proteins remained almost unaffected (Fig. 3C).
Because the 650-bp LTR transposon contains only 7
dispersed CG pairs, and no CpG island is present in the
proximal sequences (Fig. 4), this result suggests that
the regulatory effect of methylation resides outside and
far from the LTR promoter.
In vitro evaluation of the B3GALT5 promoter
To confirm the hypothesis that the B3GALT5 LTR
promoter, although necessary, is unable to regulate
transcription per se, we performed luciferase assays with
a reporter plasmid, in which luciferase is placed under
the control of the LTR sequence, and EMSAs, with the
LTR sequence used as a probe. Taking advantage of the
availability of cell lines and clones showing various
combinations of the expression levels of the B3GALT5
LTR transcript and HNF1/ proteins, we used them
as the host cells for transfecting the LTR/luciferase
plasmid or as the sources for extracting nuclear protein
to be tested with the LTR probe by EMSA.
As shown in Fig. 5A, by luciferase reporter assay, the
highest activity was found in the MKN-45 cells, which
expressed high levels of both HNF1 and HNF1 and
moderate levels of LTR transcript, followed by the
Huh-7 cells and MDA-MB-231 clone -1, which ex-
pressed high levels of HNF1 only and no or low LTR
transcripts. Conversely, much lower luciferase activity
Figure 4. CpG islands detected in the context
of the B3GALT5 gene. The genomic sequence
of chromosome 21 (0.26 Mbp) encompassing
B3GALT5 and intergenic regions was analyzed
with EMBOSS Cpgplot software (EMBL), with
the following parameters: observed:expected
ratio 0.6, C	G 50%, and minimum length,
120 bp. One CpG island was present near exon
1A, which regulates the cognate promoter (11). Several shorter stretches of CpG dinucleotides were instead detectable in the
intergenic regions.
Figure 3. Effect of TSA and 5AZA treatment on the expression of B3GALT5 LTR transcript in cultured cells. A) MKN-45 cells
were treated with various amounts of the histone deacetylase inhibitor TSA. B) MKN-45 and COLO-205 cells were treated with
various amounts of the DNA methyltransferase inhibitor 5AZA for different times. In both instances, detection and
quantification of B3GALT5 LTR transcript by competitive RT-PCR were performed as in Fig. 1. Treatments were performed in
duplicate. At the end of the treatments, cells were harvested, washed with PBS, and processed to extract RNA and nuclear
protein from the same cell suspension. Results are means  sd of 2 determinations performed on each duplicate. C) Nuclear
protein extracted from representative data points were subjected to Western blot analysis, as reported in Fig. 1.
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was detected in the SW-1116 cells, expressing high
levels of transcript and moderate levels of HNF1. In
the MDA-MB-361 cells expressing moderate levels of
transcript but low HNF1 alone, luciferase activity was
minimal, and almost undetectable in the MDA-MB-231
clone -1, which expresses minimal amounts of both
LTR transcript and HNF1. We also transfected HEK-
293T cells, which lack expression of HNF1/ and
Cdx1/2 and can replicate plasmids with the SV40
origin of replication (pcDNA3), in the presence of
transcription factor cDNAs cloned in the pcDNA3
vector. The addition of each plasmid coding HNF1/
or Cdx1/2 enhanced luciferase activity (Fig. 5B), with a
preference for HNF1 followed by HNF1 and Cdx2,
whereas Cdx1 was less effective.
By EMSA, we found that the LTR sequence, when
used as a probe, formed 1 specific complex plus 1 or 2
other nonspecific complexes (Fig. 6). The single spe-
cific complex was the most retarded and appeared as a
doublet, corresponding to HNF1/ binding. In fact, it
was found only with nuclear protein extracted from cell
lines expressing HNF1/, was affected by the anti-
HNF1 antibody, and was outcompeted by an excess of
the unlabeled probe sequence (Fig. 6A). The complex
was also evident with nuclear proteins extracted from
cells expressing very low to undetectable levels of LTR
transcript but very high levels of HNF1, such as the
Huh-7, Hep-3B, and MDA-MB-231 clones -1 or -3.
The complex was detectable but much less evident with
the protein extracted from the MDA-MB-361 cells,
which expressed moderate levels of LTR transcript and
low levels of HNF1, and was undetectable with the
MDA-MB-231 clone -1, which expressed very low levels
of both. The other complexes were not outcompeted
by the unlabeled probe and should be considered
nonspecific (Fig. 6B). In particular, the complex that
migrated as the less retarded doublet was formed by
almost any nuclear extract, including those prepared
from cells not expressing B3GALT5 LTR and unable to
drive luciferase activity on transfection with the LTR
construct. It migrated much faster than true Cdx1 or
Cdx2 complexes formed by the same LTR probe with
authentic Cdx1 or Cdx2 protein and was not competed
out by the SIF1 sequence, as occurred with the true
Cdx1 or Cdx2 complexes formed by recombinant fac-
tors (Fig. 6C). Although the LTR promoter bound
Cdx1/2 in vitro, taken together, the data indicate that
the HNF1 binding site is the only functional sequence
brought about by the insertion of the LTR transposon.
DISCUSSION
We observed that HNF1 and HNF1 are necessary to
activate the B3GALT5 LTR promoter, playing an inter-
changeable and not cumulative role, but they are
unable to modulate transcription, which instead de-
pends on the distal regulatory elements that are active
when methylated and are unknown at present.
The complex role played by HNF1 was defined by
several lines of evidence. First of all, in any cell line
lacking both HNF1 and HNF1, the B3GALT5 LTR
transcript was always undetectable; moreover, transfec-
tion of one of these cells with either HNF1 or HNF1
cDNA induced LTR transcription. In addition, shRNA-
mediated silencing of HNF1 in cells expressing only
HNF1 strongly impaired LTR expression. These re-
sults clearly indicate that HNF1 is necessary for tran-
scription. Because the transcript was detected in cell
lines and clones expressing either HNF1 or HNF1
alone, and shRNA-mediated silencing of HNF1 in
cells expressing both HNF1 and HNF1 does not
affect LTR expression, the two forms appear to be not
cooperative, but interchangeable, as reported in the
gut (21), but not in the kidney (22). On the other
hand, the expression levels of either HNF1 form, or of
both forms when expressed together, cannot explain
the wide expression range of the LTR transcript. In
Figure 5. Luciferase activity assay of the B3GALT5
LTR promoter. The genomic sequence148 to
128, calculated from the transcription initia-
tion site of B3GALT5 LTR mRNA, encompass-
ing part of the LTR transposon, was cloned in
the pGl3 vector carrying the firefly luciferase
gene (pGl3-LTR) and transfected together with
a Renilla luciferase reporter expression plasmid
in various host cells. A) Host cells were from
cell lines or clones that express the different
amounts of HNF1/ and B3GALT5 LTR tran-
script shown in Figs. 1 and 2. The pGL3-control
vector, bearing the SV40 promoter, and the
pGl3-basic vector, lacking any promoter se-
quence, were also transfected for normalization
and control. Firefly luciferase activity was measured 24 h later, calculated relative to the Renilla luciferase activity determined for
each sample, and expressed as a fraction of the activity measured with the pGL3-control in the same host cells. B) pGL3-LTR
and Renilla luciferase plasmids were mixed with expression plasmids having the coding region of transcription factors cloned
in the pcDNA3 vector, which bears the SV40 origin of replication, and were transfected into HEK-293T cells, which are able to
replicate plasmids with the SV40 origin of replication. Firefly luciferase activity was measured 24 h later and expressed relative
to the Renilla luciferase activity determined for each sample. Transfection with pGL3-LTR and Renilla luciferase plasmids mixed
with pcDNA3 vector alone was performed as the control. Results are expressed as means  sd of 2 experiments performed in
triplicate.
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fact, comparable amounts of HNF1 were detected in
the COLO-205 or SW-1116 cells, which expressed the
highest levels of LTR transcript, and in the cells, clones,
or colon cancer biopsies, which expressed 10- or 100-
fold less, or even undetectable, LTR transcript. This
evidence prompts the question of what other factor or
mechanism affects B3GALT5 LTR transcription and is
responsible for cancer down-regulation. We found that
Cdx1 and Cdx2 were not involved, although they
bound and activated the LTR promoter in vitro. In fact,
the amounts of Cdx1/2 in cells or tissues expressing the
B3GALT5 LTR transcript were negligible, and the few
samples expressing detectable amounts of Cdx2
(HCT-15 cells and colon cancer biopsies 1 and 2)
lacked B3GALT5 LTR transcript. Moreover, nuclear
protein extracted from cells expressing the transcript
never formed Cdx1/2 complexes in the EMSAs, and
the less retarded doublet detected by EMSA with the
LTR probe and previously proposed to depend on
Cdx1/2 binding (7) did not behave as true Cdx1/2
complexes, but was found to be a nonspecific artifact
formed by any nuclear protein extract, including those
from cells not expressing the transcript at all. Alto-
gether, these data indicate that the HNF1 binding site
is the only functional part of the LTR promoter and
that no other binding sites for stimulatory or inhibitory
factors, including Cdx1/2, are physiologically relevant.
Conversely, DNA demethylation, obtained through
5AZA treatment of cells expressing the B3GALT5 LTR
transcript, reproduced in vitro the down-regulation of
the transcript observed among cell lines and cancer
biopsies in vivo. In fact, in treated cells, the levels of
B3GALT5 LTR transcript decreased from 3 or 10 fg/pg
-actin to 
0.2 fg/pg, whereas the amounts of HNF1
remained almost unchanged. LTR and proximal se-
quences do not contain CpG islands, and we therefore
conclude that methylation-sensitive DNA sequences
represent elements involved in transcriptional regula-
tion residing outside the LTR sequence, probably dis-
tant from the promoter. Alignment of the LTR se-
quence and the whole B3GALT5 gene in the context of
chromosome 21 (Fig. 4) revealed a single typical pro-
moter-associated CpG island, already characterized in
detail and responsible for regulating transcription of
native B3GALT5 mRNA (11). In addition, several very
short CpG islands were detected: one in an intron and
the others in the intergenic regions. Unfortunately,
because of the extremely high homology of this human
Figure 6. Characterization of the bind-
ing properties of the B3GALT5 LTR
promoter. EMSAs were performed by
incubating a biotinylated oligonucleo-
tide probe (nt 151 to 112, calcu-
lated from the transcription initiation
site of B3GALT5 LTR mRNA) with
nuclear protein extracted from cell
lines or clones expressing the different
amounts of HNF1/ and B3GALT5
LTR transcripts shown in Figs. 1 and 2,
as well as from HEK-293T cells expressing
recombinant Cdx1 or Cdx2 (Supple-
mental Fig. S1B). Competitor oligonu-
cleotides were the unlabeled oligonucle-
otide probe (self), the consensus sequence
of AP2 (5=-GATCGAACTGACCGCCCG-
CGGCCCGT-3=) used as an irrelevant
DNA control, and the consensus sequence of Cdx1/2 deduced from the sucrase-isomaltase promoter (SIF1) reported by
Suh et al. (20). They were present in 100-fold molar excess in the incubation mixture, unless differently indicated. The
resultant complexes were separated by 5% native PAGE and visualized by chemiluminescence. A) MKN-45, SW-1116, and
MDA-MB-361 cells expressed the B3GALT5 LTR transcript, whereas Hep-3B cells did not. B) No cell line expressed the
B3GALT5 LTR transcript. C) MDA-MB-231 cells did not express the B3GALT5 LTR transcript, whereas clones expressed low
levels of the transcript, and COLO-205 and SW-1116 cells expressed high levels.
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sequence with that of the other primates sharing the
LTR transposon, no prediction can be made in silico
about the relevance of any of these islands. Alterna-
tively, the region involved could be 0.1 Mbp away
from the LTR sequence.
We thus propose a model of B3GALT5 transcription
predicting that a distant DNA region, methylated in
normal colon mucosa and cell lines, such as COLO-205
or SW-1116, is demethylated in colon cancer, in several
cell lines, and even in other tissues still expressing
HNF1. The degree of demethylation down-regulates
transcription to complete silencing, as in the Hep-3B
and Huh-7 cells in this study.
DNA hypomethylation was indeed the first epige-
netic abnormality detected in human cancers 30 yr
ago (23). However, it has received much less attention
in the past decade than the opposite modification,
hypermethylation, frequently associated with silencing
of tumor-suppressor and other genes. Only recently,
high-resolution, genome-wide analyses revealed an in-
dependent and relevant role of hypomethylation in
cancer formation and progression (24, 25). Among
various DNA sequences affected by cancer-associated
hypomethylation, transcription control elements ap-
peared to be of special interest. In particular, it was
found that genes associated with hypermethylated dis-
tant control elements are more frequently down-regu-
lated in cancer (26).
No information about the nature, exact location, or
mechanism of action of such a distant sequence is
available for B3GALT5 transcription at present. It may
represent a typical CpG island, or a “shore,” as recently
proposed (27), or instead include stretches of CpG
dinucleotides shorter than the CpG islands associated
with promoters, such as those present in the intergenic
regions of B3GALT5. Methylation of such stretches of
CpG dinucleotides is emerging as a relevant aspect of
transcriptional control (28) and is responsible for
recruitment of alternative promoters, regulation of
noncoding RNA synthesis, and modulation of enhancer
activity. In particular, hypomethylation of enhancer
sequences is reported to negatively regulate transcrip-
tion in cancer and during tissue differentiation (28).
The occurrence of distal regulatory elements that bind
transcription factors in a methylation-dependent man-
ner was recently reported in breast cancer (29). Other
types of genome-wide analyses have indicated that
HNF1 can play such a role in the kidney (30) and in the
liver (31). B3GALT5 transcription thus represents a
promising model to address such novel issues, since
hypomethylation of distant sequences, acting on the
LTR transcript, and promoter hypermethylation, acting
on the native transcript (11), cooperate on one gene to
obtain full cancer-associated silencing.
Our present findings also contribute to a better
understanding of the mechanism of evolutionary stabi-
lization of the LTR transposon in comparison with the
models hypothesized for other mobile elements (32).
In fact, reported evidence suggests that the transposon
is already active at the time of insertion (9) and may
take advantage of the analogous sequence present in
the type B promoter, which is much less active because
of its opposite orientation (10). We now propose that
effective interaction with a distant element plays a crucial
stabilizing effect, probably due to the precise localization
of insertion, which in turn allows not only stronger
HNF1-associated expression, but also the most precise
tissue specificity, obtained through the overlapping epi-
genetic control exerted by the distal element.
A.Z. was supported by the Ph.D. Program in Molecular
Medicine of the University of Milan.
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